Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2024) 99 EP371 | DOI: 10.1530/endoabs.99.EP371

ECE2024 Eposter Presentations Pituitary and Neuroendocrinology (214 abstracts)

Macroprolactinoma diagnosis and treatment in the setting of schizophrenia

Gabriel Tan 1


1Tan Tock Seng Hospital, Singapore, Singapore


Prolactinomas are the most common pituitary lesion, and respond well to treatment with dopamine agonists. It presents a diagnostic and therapeutic challenge when there is concurrent psychosis, the treatment of which involves dopamine antagonists. A 69-year-old post-menopausal lady with schizophrenia, on olanzapine 5mg ever, evening, presented with unstead, gait. MRI brain scan showed a 3.3 x 1.8 x 2.4 cm pituitary macroadenoma with optic chiasm indentation. Visual field testing showed bitemporal hemianopia. There was marked hyperprolactinemia, low free thyroxine with inappropriatel, normal TSH, inappropriate low FSH and LH for post-menopausal state. Her ACTH stimulation test was robust. She was diagnosed with macroprolactinoma complicated by visual involvement, central hypothyroidism, central hypogonadism. After discussion with psychiatry and neurosurgery olanzapine was stopped and she started on bromocriptine and levothyroxine. She developed giddiness with bromocriptine, hence we switched to cabergoline 0.25mg/week with gradual dose escalation. Follow up showed improvement in her prolactin and free thyroxine. Repeat MRI demonstrated interval decrease in macroadenoma size (2.7 x 2.2 x 1.7 cm) and reduced mass effect on the optic chiasm with clinical improvement in visual fields. This case illustrates diagnostic pitfalls in hyperprolactinemia. Prolactin should be checked in all pituitary lesions. After excluding high dose hook effect, the degree of prolactin elevation can help differentiate between prolactinoma, stalk effect or drug induced hyperprolactinemia. Antipsychotics may worsen hyperprolactinemia, enhance macroprolactinoma growth, and blunt effect of dopamine agonist treatment. Cessation of her antipsychotics needs to be balanced against risk of psychotic exacerbation. Close psychiatry follow-up and cautious uptitration of dopamine agonists is recommended.

Investigations 06/10/2022
TestUnitsReference
Prolactin (on dilution) 80.37091–650 mIU/l
ACTH8.31.6–13.9 pmol/l
Cortisol 8am294nmol/l
Cortisol 0 min (at 2pm) 194nmol/l
Cortisol 30 min509
Cortisol 60 min616
Free thyroxine78–16 pmol/l
TSH2.020.45–4.5 mIU/l
Luteinizing hormone<111–59 IU/l
Follicular stimulating hormone117–144 IU/l
Estradiol<73pmol/l
IGF-167 mg/l 54–163 mg/l
Sodium145 mmol/l135–145 mmol/l
Potassium3.2 mmol/l3.5–5.1mmol/l
Creatinine53 umol/l40-75 umol/l
Follow up
TestDateValueTreatment
Prolactin06/10/202280.370Bromocriptine 1.25mg ON then 2.5mg ON
03/11/202231,658Bromocriptine 5mg ON
28/11/202249,352Cabergoline 0.25mg once/week then 0.25mg 2 times/week
19/01/202320.561
03/03/20235518
TestDateValueTreatment
Free thyroxine06/10/20227Levothyroxine 25 mg OM
03/11/202210
19/01/202310Levothyroxine 50 mg OM
09/03/202311

Volume 99

26th European Congress of Endocrinology

Stockholm, Sweden
11 May 2024 - 14 May 2024

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.